Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu-177-Therahexin-503
- Development stage
- Unknown
- Lead developer
- TRIMT
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Lu-177-Therahexin-503 is a radioligand therapeutic consisting of the beta-emitting radioisotope Lutetium-177 conjugated to Therahexin-503, a peptide-based ligand targeting the "cancer integrin" αvβ6. This integrin is highly expressed in various carcinomas, including breast cancer and pancreatic ductal adenocarcinoma, while showing low expression in healthy tissues. Developed by TRIMT GmbH, the drug is designed for targeted radioligand therapy (RLT), delivering ionizing radiation directly to tumor cells to induce DNA damage and cell death. It has demonstrated high tumor uptake and favorable dosimetry in early clinical case studies for metastatic breast cancer and pancreatic cancer.
- Other names
- Lu-177-TherahexinLu177-TherahexinLu 177-Therahexin177Lu-Therahexin-503177Lu-Therahexin
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on Lu-177-Therahexin-503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu-177-Therahexin-503.